# A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS

> **NCT01986166** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** MEHD7945A

## Key facts

- **NCT ID:** NCT01986166
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2016-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986166, "A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01986166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*